BiotechTube

Drug Product De-TIL-0255

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum-resistant Ovarian Cancer

Conditions

Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer

Trial Timeline

Dec 22, 2021 → May 9, 2023

NCT ID
NCT05107739

About Drug Product De-TIL-0255

Drug Product De-TIL-0255 is a phase 1 stage product being developed by Nurix Therapeutics for Platinum-resistant Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05107739. Target conditions include Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer.

What happened to similar drugs?

0 of 3 similar drugs in Platinum-resistant Ovarian Cancer were approved

Approved (0) Terminated (1) Active (2)
❌Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
🔄Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
🔄olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05107739Phase 1Terminated

Competing Products

16 competing products in Platinum-resistant Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
E7050 + CetuximabEisaiPhase 1/2
32
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
31
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
24
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
31
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
32
CRS-207 + Epacadostat + PembrolizumabIncytePhase 1/2
21
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
41
Bevacizumab + Irinotecan SucrosofateIpsenPhase 2
32
Gemcitabine + N-803 + M-CENKImmunityBioPhase 2
39
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154Shattuck LabsPhase 1
19
CTIM-76Context TherapeuticsPhase 1
26
LorigerlimabMacroGenicsPhase 2
32
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3
37
PHI-101 administrationiBioPhase 1
15